Royce & Associates LP Viking Therapeutics, Inc. Transaction History
Royce & Associates LP
- $10.5 Billion
- Q3 2024
A detailed history of Royce & Associates LP transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Royce & Associates LP holds 13,334 shares of VKTX stock, worth $420,287. This represents 0.01% of its overall portfolio holdings.
Number of Shares
13,334Holding current value
$420,287% of portfolio
0.01%Shares
5 transactions
Others Institutions Holding VKTX
# of Institutions
465Shares Held
63.9MCall Options Held
5.76MPut Options Held
3.4M-
Vanguard Group Inc Valley Forge, PA10.2MShares$320 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$190 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$147 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$66.7 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$59.1 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $2.42B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...